The uninsured rates may skyrocket when Medicaid work requirements go into effect and if the Affordable Care Act (ACA) ...
A retrospective analysis of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy outcomes ...
Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...
GDF15 and OPN show promise in differentiating uterine sarcoma from leiomyoma, outperforming traditional markers like LDH and ...
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve. Stay ahead ...
Soluble TAM receptors (sTAMs) could serve as biomarkers for RA, indicating disease activity, severity, and prognosis, though standardized detection methods are needed. TAM receptors could emerge as ...
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...
“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback